On December 11, 2023 Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, reported to present a detailed preclinical profile for KRLS-017 at AACR (Free AACR Whitepaper) 2024 in San Diego, CA (Press release, Kirilys Therapeutics, DEC 11, 2023, View Source [SID1234638566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KRLS-017 is a potent, selective, and reversible inhibitor of Cyclin Dependent Kinase 7 (CDK7) and is being developed for the treatment of patients with advanced solid tumor malignancies. CDK7 function in control of both cell cycle and gene transcription, and overexpression of CDK7 is a poor prognostic indicator in breast, ovarian, gastric, and other tumor types.

The preclinical presentation titled "Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignancies" will include pharmacology, toxicology, and efficacy across several dosing schedules using in vivo tumor models. A Phase 1 clinical program for KRLS-017 is planned as a monotherapy dose escalation study in refractory solid tumors followed by an indication-specific cohort expansion that will include breast, ovarian and potentially other transcriptionally active tumor types to evaluate anti-tumor activity.